1507-14-8

Basic information

• Product Name: 1-(2-Hydroxyethyl)-3,7-dimethylxanthine
• Synonyms: 1-(2-Hydroxyethyl)-3,7-dimethylxanthine;1-(2-Hydroxyethyl)theobromine;3,7-Dihydro-1-(2-hydroxyethyl)-3,7-dimethyl-1H-purine-2,6-dione
• CAS NO: 1507-14-8
• Molecular Formula: C9H12 N4 O3
• Molecular Weight: 224.2166
• Mol File: 1507-14-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 165-166 °C
• Boiling Point: 502.1°Cat760mmHg
• Flash Point: 257.5°C
• Appearance: /
• Density: 1.51g/cm³
• Vapor Pressure: 6.67E-11mmHg at 25°C
• Refractive Index: 1.683
• PKA: 14.40±0.10(Predicted)
• CAS DataBase Reference: 1-(2-Hydroxyethyl)-3,7-dimethylxanthine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Hydroxyethyl)-3,7-dimethylxanthine(1507-14-8)
• EPA Substance Registry System: 1-(2-Hydroxyethyl)-3,7-dimethylxanthine(1507-14-8)

Safety Data

• Hazardous Substances Data: 1507-14-8(Hazardous Substances Data)

Usage

General Description

1-(2-Hydroxyethyl)-3,7-dimethylxanthine is a chemical compound belonging to the xanthine class of alkaloids. It is commonly known as theobromine, and it is found in a variety of natural sources, including cacao beans, tea leaves, and kola nuts. Theobromine is a stimulant that affects the central nervous system, similar to caffeine, although it is less potent. It also has diuretic and smooth muscle relaxant properties. Theobromine is often used in pharmacology and medicine as a vasodilator and in the treatment of various respiratory conditions. Additionally, it has also been studied for its potential antioxidant and anti-cancer properties. Overall, theobromine has a range of biological effects and potential medicinal applications.

InChI:InChI=1/C9H12N4O3/c1-11-5-10-7-6(11)8(15)13(3-4-14)9(16)12(7)2/h5,14H,3-4H2,1-2H3

Upstream product

• 75-21-8 oxirane 
• 83-67-0 theobromine / 
• 107-07-3 2-chloro-ethanol 
• 540-51-2 2-bromoethanol 
• 75449-03-5 (3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-purine-1-yl) acetic acid ethyl ester 
• 1010-59-9 theobromine sodium salt 
• 624-76-0 Iodoethanol 

Downstream Products

• 56865-08-8 1-(2-chloroethyl)-3,7-dimethyl-2,3,6,7-tetrahydro-1H-2,6-purinedione 
• 234432-02-1 1-(2-hydroxy-ethyl)-3,7-dimethyl-8-phenylsulfanyl-3,7-dihydro-purine-2,6-dione 
• 47043-84-5 1-(2-diethylamino-ethyl)-3,7-dimethyl-3,7-dihydro-purine-2,6-dione 
• 1220124-84-4 1-(2-hydroxyethyl)-3,7,9-trimethylxanthinium iodide 

Relevant articles and documents

Compound for treating pneumonia and application thereof

The invention discloses a compound for treating pneumonia and application thereof, and relates to the technical field of medicines. The compound for treating pneumonia is a heterocyclic compound, a pharmaceutically acceptable salt of the heterocyclic compound and/or a pharmaceutically acceptable carrier of the heterocyclic compound. The compound for treating pneumonia has a significant improvementeffect on bacterial pneumonia, viral pneumonia, fungal pneumonia, immune pneumonia, mycoplasma pneumonia, chlamydia pneumonia and other pathogen pneumonia, and especially can significantly improve pathological damage of viral bacterial pneumonia. The heterocyclic compound involved in the compound for treating pneumonia is simple in synthesis method, is suitable for industrial production, and is more stable than natural analogues; the activity of the compound is remarkably superior to that of ribavirin, oseltamivir, cefazolin and penicillin G which are clinically first-line medicines, and theactivity of the compound is also remarkably superior to that of purine analogues A, B and C.

Synthesis and anticancer activity of silver(I)-N-heterocyclic carbene complexes derived from the natural xanthine products caffeine, theophylline and theobromine

A new library of silver(I)-N-heterocyclic carbene complexes prepared from the natural products caffeine, theophylline and theobromine is reported. The complexes have been fully characterised using a combination of NMR spectroscopy, mass spectrometry, elemental analysis and X-ray diffraction analysis. Furthermore, the hydrophobicity of the complexes has been measured. The silver(I)-N-heterocyclic carbenes have been evaluated for their antiproliferative properties against a range of cancer cell lines of different histological types, and compared to cisplatin. The data shows different profiles of response when compared to cisplatin in the same panel of cells, indicating a different mechanism of action. Furthermore, it appears that the steric effect of the ligand and the hydrophobicity of the complex both play a role in the chemosensitivity of these compounds, with greater steric bulk and greater hydrophilicity delivering higher cytotoxicity.

Characterization of 'mini-nucleotides' as P2X receptor agonists in rat cardiomyocyte cultures. An integrated synthetic, biochemical, and theoretical study

The design and synthesis of 'mini-nucleotides', based on a xanthine- alkyl phosphate scaffold, are described. The physiological effects of the new compounds were evaluated in rat cardiac cell culture regarding Ca2+ elevation and contractility. The results indicate biochemical and physiological profiles similar to those of ATP, although at higher concentrations. The biological target molecules of these 'mini-nucleotides' were identified by using selective P2-R and A1-R antagonists and P2-R subtype selective agonists. On the basis of these results and of experiments in Ca2+ free medium, in which [Ca2+](i) elevation was not observed, we concluded that interaction of the analogues is likely with P2X receptor subtypes, which causes Ca2+ influx. Theoretical calculations analyzing electronic effects within the series of xanthine-alkyl phosphates were performed on reduced models at quantum mechanical levels. Calculated dipole moment vectors, electrostatic potential maps, and volume parameters suggest an explanation for the activity or inactivity of the synthesized derivatives and predict a putative binding site environment for the active agonists. Xanthine-alkyl phosphate analogues proved to be selective agents for activation of P2X-R subtypes, whereas ATP activated all P2-R subtypes in cardiac cells. Therefore, these analogues may serve as prototypes of selective drugs aiming at cardiac disorders mediated through P2X receptors.